Skip to content
CG

Centuple Global

531099 BSE
Price unavailable

Centuple Global (CENTUPLE) share price was ₹37.23 at the 28 Oct 2026 close; market capitalisation ₹20.41 Cr; P/E (TTM) 16.62; sector Healthcare. The share price fell 42.1% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 100.0% year on year to under ₹0.1 Cr and net profit was −₹0.18 Cr, against ₹0.09 Cr a year earlier (compared with Jun 2025). Promoters held 0.00% of Centuple Global in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 42/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹37.23 −28.36 −43.24% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹20.41 Cr
P/E (TTM)
16.62
EBITDA
₹2.30 Cr
Return on Equity
6.49%
Debt to Equity
0.3
Book Value
₹3.78
EPS (TTM)
₹2.24
52W High
₹144.40
52W Low
₹28.42

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.2035.064,24,010 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,604.5072.281,75,140 Cr9.530.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.30108.071,18,182 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.0026.281,17,805 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.4034.661,11,714 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,362.5032.641,10,071 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Centuple Global (this company)
—16.6220 Cr9.850.00%6.49%9.83%562 Cr1 Cr
Median 8 companies₹1,767.2034.861,17,994 Cr7.300.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

42 Weak
Overall score

Data confidence 98/100

Category scores

Quality Poor 25
Returns, margins, earnings quality 22% weight
Valuation Weak 41
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Poor 21
Solvency, leverage, coverage 9% weight
Momentum Poor 17
Trend strength, vol-adjusted 12% weight
Ownership Good 56
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Stock is trading at 0.77 times its book value
  • Company's median sales growth is 26.2% of last 10 years
  • Company's working capital requirements have reduced from 182 days to 14.7 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 12.3% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 215 days.

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
4
Bullish
2

Overall

Bullish

Bearish
6
Neutral
4
Bullish
9

Moving Averages

Bullish

Bearish
3
Neutral
0
Bullish
7

Growth Rate

Revenue Growth
—

Net Income Growth
—

Cash Flow Change
—

EBITDA Margin Change
-96.4%

change over 1 year

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0.2
0.29
0.17
0.47
0.1
0.05
0.1
0.25
11.71
109
174
279
0
Expenses
0.25
0.03
0.11
0.71
0.07
0.08
0.14
0.16
11.62
107
173
280
0.18
Operating Profit
-0.05
0.26
0.06
-0.24
0.03
-0.03
-0.04
0.09
0.09
1.8
0.77
-0.37
-0.18
OPM %
-25%
89.66%
35.29%
-51.06%
30%
-60%
-40%
36%
0.77%
1.66%
0.44%
-0.13%
—
Other Income
0
0
0
0
0
0
0.02
-0.02
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
-0.05
0.26
0.06
-0.24
0.03
-0.03
-0.02
0.07
0.09
1.8
0.77
-0.37
-0.18
Tax %
0%
0%
0%
-4.17%
0%
33.33%
0%
0%
0%
26.11%
25.97%
27.03%
0%
Net Profit
-0.05
0.26
0.06
-0.23
0.02
-0.04
-0.02
0.06
0.09
1.32
0.57
-0.48
-0.18
EPS (₹)
-0.09
0.48
0.11
-0.42
0.04
-0.07
-0.04
0.11
0.16
2.41
1.04
-0.88
-0.33
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
2
1
1
0
2
1
1
0
574
562
Expenses
0
0
0
2
1
1
0
2
1
1
0
572
560
Operating Profit
0
0
0
0
0
0
0
0
0
0
0
2
2
OPM %
—
-5%
10%
-1.3%
-31%
2%
2%
-1%
-7%
2.6%
20%
0.4%
0.4%
Other Income
-3
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
-3
0
0
0
0
0
0
0
0
0
0
2
2
Tax %
0%
0%
0%
0%
0%
20%
0%
50%
0%
-50%
40%
34%
—
Net Profit
-3
0
0
0
0
0
0
0
0
0
0
2
1
EPS (₹)
-5.61
-0.02
0.05
-0.29
-0.02
0.05
0.02
-0.07
-0.15
0.05
0.05
2.76
2.24
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
-5
-5
-5
-5
-5
-5
-5
-5
-5
-5
-5
18
Borrowings
0
0
0
0
0
0
0
0
0
0
0
7
Other Liabilities
0
0
0
0
0
0
0
0
0
0
0
313
Total Liabilities
0
0
1
1
1
1
1
1
1
1
1
343
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
0
0
1
1
1
1
1
1
1
1
1
343
Total Assets
0
0
1
1
1
1
1
1
1
1
1
343
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
0
0
0
0
0
1
0
0
0
0
-28
Investing
0
0
0
0
0
0
0
0
0
0
0
0
Financing
0
0
0
0
0
0
0
0
0
0
0
28
Net Cash Flow
0
0
0
0
0
0
1
0
0
0
0
0
Free Cash Flow
0
0
0
0
0
0
1
0
0
0
0
-28
CFO/OP
114
100
133
-600
17
650
5,200
2,450
-12
0
190
-1,223
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
54
179
107
—
122
135
229
—
215
Inventory Days
—
—
—
0
0
0
—
0
—
—
—
1
Days Payable
—
—
—
—
—
—
—
—
—
—
—
197
Cash Conversion Cycle
—
—
—
54
179
107
—
122
135
229
—
19
Working Capital Days
—
—
—
36
260
221
—
98
129
145
—
15
ROCE %
-3%
-3%
7%
25%
-31%
3%
2%
-3%
-13%
3%
17%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Centuple Global insights

59 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Public71.92%Others8.93%FIIs19.14%As ofSep 2026

Documents

Frequently Asked Questions about Centuple Global

What does Centuple Global Ltd do?
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Where is Centuple Global Ltd (CENTUPLE) listed?
Centuple Global Ltd trades under code 531099 on the BSE.
Which sector does Centuple Global Ltd belong to?
Centuple Global Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Centuple Global Ltd?
Centuple Global Ltd has a market capitalisation of ₹20.41 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Centuple Global Ltd?
Centuple Global Ltd trades at a PE ratio of 16.62 as of 28 Oct 2026, on earnings per share of ₹2.24, against a book value of ₹3.78 per share.
What is the 52-week high and low of Centuple Global Ltd?
Over the last 52 weeks Centuple Global Ltd has traded between ₹28.42 and ₹144.4 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Centuple Global Ltd?
Centuple Global Ltd reported a return on equity of 6.49%. Its debt-to-equity ratio is 0.30.

Company Information

Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]

Website rubramed.com
Face Value ₹ 10
Shares Outstanding 54,82,581

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531099.md for Centuple Global Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month